Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma.

Saved in:
Bibliographic Details
Title: Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma.
Authors: Paczkowska J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tang M; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Astra Zeneca, Waltham, MA, USA., Wright KT; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Song L; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biomedical Data Science, Dartmouth College, Hanover, NH, USA., Luu K; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.; PathAI, Boston, MA, USA., Shanmugam V; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Welsh EL; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Weirather JL; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Besson N; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Olszewski H; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Porter BA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pfaff KL; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Redd RA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Cader FZ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; AstraZeneca, City House, Cambridge, UK., Mandato E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ouyang J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Mechanisms of Cancer Resistance Thematic Center, Bristol Myers Squibb, Cambridge, MA, USA., Calabretta E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bai G; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, USA., Lawton LN; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Liu XS; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, USA.; GV20 Therapeutics, LLC, Cambridge, MA, USA., Shipp MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Margaret_Shipp@dfci.harvard.edu.
Source: Nature communications [Nat Commun] 2024 Dec 30; Vol. 15 (1), pp. 10740. Date of Electronic Publication: 2024 Dec 30.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-1723
DOI:10.1038/s41467-024-54512-7